AZD 0902
Alternative Names: AZD0902Latest Information Update: 02 Nov 2005
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Rheumatoid arthritis
Most Recent Events
- 02 Nov 2005 Discontinued - Preclinical for Rheumatoid arthritis (unspecified route)
- 04 Aug 2004 Discontinued - Preclinical for Chronic obstructive pulmonary disease (unspecified route)
- 28 Oct 2003 Preclinical trials in Rheumatoid arthritis (unspecified route)